Collectively, these data support a dual perspective: IGFBP-6 participates in HCC biology both as a candidate circulating analyte whose levels diverge from chronic hepatitis and as a biochemical gatekeeper whose O-GlcNAc status may tune the fraction of bioactive IGF-II available to tumor and stromal receptors. Here, IGFBP6 is linked to neoplasm.